Contract Pharma Manufacturing News

  1. Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas 2/26/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. 

  2. Eckert & Ziegler Enters Partnership With Molecular Partners To Support Development Of Radio-DARPin Therapeutics 2/26/2026
  3. Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment 2/26/2026

    Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

  4. SK bioscience, IDT Biologika And Vaxxas Selected For Next-Generation Influenza Vaccine Development Financed By The European Union 2/26/2026

    SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital Executive Agency (HaDEA) on behalf of the European Commission's Health Preparedness and Response Authority (HERA).

  5. ESTEVE CDMO Commences $15.5M Expansion Of Chicago Small Molecule API Facility 2/26/2026

    ESTEVE CDMO, the global pure-play CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, today announced that it had commenced a $15.5-M investment to enhance production capabilities and associated space at its newly acquired North American facility in Morton Grove, Illinois.

  6. Andelyn Biosciences To Apply the AAV Curator® Platform To Manufacture Clinical Grade AAV For Drake Rayden Foundation For The Treatment Of Nonketotic Hyperglycinemia 2/25/2026

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator® Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.

  7. Nu-Tek BioSciences Reinforces Global Supply Leadership With Halal Certification Renewal 2/25/2026

    Nu-Tek BioSciences, the industry leader in 100% animal-origin-free (AOF) peptones and yeast extracts, announced today that it has successfully renewed its Halal certification from The Islamic Food and Nutrition Council of America (IFANCA).

  8. Nu-Tek BioSciences To Highlight Animal-Origin-Free Peptones, Supply Chain Strength At DCAT Week 2026 2/25/2026

    Nu-Tek BioSciences, the market leader in 100% animal-origin-free (AOF) peptones and yeast extracts, announced today that it will participate in the upcoming Drug, Chemical and Associated Technologies (DCAT) Week 2026, hosted March 23–26 in New York City. 

  9. Scinai Announces Expanded Israel Innovation Authority Support For Robotic Aseptic Fill & Finish Platform 2/25/2026

    Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.

  10. Novartis To Build New Radioligand Therapy Site In Denton, Texas, Delivering More Next Generation Treatments To Patients 2/25/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing facility in Texas, and marks further progress in the company’s $23B US investment.